S&P Futures
4,256.25 -8.50 (-0.20%) Dow Futures
33,151.00 -50.00 (-0.15%) Nasdaq Futures
14,684.50 -30.00 (-0.20%) Russell 2000 Futures
1,737.80 -4.10 (-0.24%) Crude Oil
89.35 +0.12 (+0.13%) Gold
1,839.60 -1.90 (-0.10%)
CANbridge Pharmaceuticals Inc. (1228.HK)
Chart Events
Performance Outlook
| Previous Close | 1.550 |
| Open | 1.360 |
| Bid | 1.340 x N/A |
| Ask | 1.500 x N/A |
| Day's Range | 1.340 - 1.420 |
| 52 Week Range | 1.230 - 3.000 |
| Volume | |
| Avg. Volume | 1,593 |
| Market Cap | 602.638M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.040 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.93 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 1228.HK
Related Research
PR NewswireCANbridge to Participate in Two Investor Conferences in September
CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, today announced its participation in two upcoming investor conferences.
- PR Newswire
CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023
CANbridge Pharmaceuticals, Inc. ("CANbridge," stock code 1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare diseases and oncology indications, today announced its financial results for the six months ended June 30, 2023 plus corporate updates.
Business WireCANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee
BEIJING & BURLINGTON, Mass., July 03, 2023--CANbridge Pharma to continue CAN008 Ph 2 trial in glioblastoma multiforme in China, based on independent data monitoring committee interim analysis.
